LY2090314 is a glycogen synthase kinase-3 (GSK-3) inhibitor that has been primarily investigated for its potential in treating neurological and psychiatric disorders. It has shown research utility in models of Alzheimer's disease due to its ability to modulate tau protein phosphorylation, a key factor in neurofibrillary tangle formation. The compound has also been studied in the context of mood disorders, such as bipolar disorder and depression, where GSK-3 inhibition may contribute to neuroprotective and mood-stabilizing effects. Additionally, LY2090314 has been used in preclinical research to explore its impact on cellular proliferation and survival pathways, particularly in relation to Wnt signaling. Its application remains largely experimental, serving as a tool compound in mechanistic studies and drug development efforts targeting GSK-3-dependent conditions.